Erin O'Brien

Here’s a look at our recent coverage of these disorders in honor of Mother’s Day 2024.

Here are highlights from the week in Psychiatric Times.

What is new in research on stress and anxiety disorders?

Here are highlights from the last day of this year’s APA Annual Meeting.

“Our results indicate that prior assessments significantly underestimated the association between ambient temperature and suicide.”

Here are highlights from the fourth day of this year’s APA Annual Meeting.

Here are highlights from the third day of this year’s APA Annual Meeting.

The extension trial aims to address the cognitive impairment often observed in schizophrenia.

Here are highlights from the second day of this year’s APA Annual Meeting.

New research on tardive dyskinesia has also been featured at the 2024 APA Annual Meeting.

Here are highlights from the first day of this year’s APA Annual Meeting.

Are individuals with bipolar disorder more likely to die from unnatural causes than the general population?

What is the potential impact of social media overuse and mental health crises in young patients?

A look at the theme for the 2024 American Psychiatric Association Annual Meeting.

What is new in research on major depressive disorder?

Our Editorial Board members are delivering expert perspectives on a wide variety of psychiatric issues and disorders.

Write to us now to be part of our series focused on mental health awareness this month.

The proposed change acknowledges the medical applications of marijuana.

Here are some updates from the world of psychiatry throughout the month of April.

The experts weighed in on a wide variety of psychiatric issues for the April issue of Psychiatric Times.

Here are highlights from the week in Psychiatric Times.

What is new in research on posttraumatic stress disorder?

Here are highlights from the week in Psychiatric Times.

What is new in research on opioid use disorder?

What does the recent FDA clearance of this treatment for adolescents mean for the future of MDD treatment?

Tris Pharma has formed the organization along with a licensing agreement with Braingaze for development, distribution of the technology.

Study results suggest the potential for a scalable, single-dose treatment approach.

What are the most effective approaches to SUD treatment in this unique patient population?

How can telehealth aid in the treatment of opioid use disorders in this patient population?

Rosine Perelberg, PhD, discusses psychoanalytic thought, social anthropology, and the future of psychoanalysis.